港股异动 | 云顶新耀(01952)早盘涨超6% EVM14直击鳞癌治疗临床痛点 实现临床开发进程领跑

智通财经
Oct 21

智通财经APP获悉,云顶新耀(01952)早盘涨超6%,截至发稿,涨6.66%,报54.45港元,成交额1.42亿港元。

消息面上,据云顶新耀官微消息,10月14日,公司宣布其通用现货型肿瘤治疗性疫苗EVM14注射液的全球多中心I期临床试验在美国临床研究机构NEXT Oncology Virginia成功入组首例患者。这是继EVM14新药临床试验申请(IND)在美国食品药品监督管理局(FDA)和中国国家药品监督管理局(NMPA)均获批准后的一项重要临床进展。

智通财经APP在《云顶新耀(01952)mRNA肿瘤疫苗EVM14接连突破:中国获批临床后,美国一期首患成功入组》中指出,EVM14的研发,正直击当前鳞癌治疗的临床痛点。目前鳞癌患者群体庞大,但现有标准治疗仍未实现令人满意的治疗效果,存在巨大的未满足医疗需求。作为通用现货型疫苗,EVM14具有无需HLA筛选、可现货供应、生产成本较低、适用于多瘤种等优势,在肿瘤治疗领域展现出广阔应用前景。据预测,mRNA肿瘤疫苗市场在中性情景下规模可达406.51亿美元,其中通用型疫苗因成本优势,渗透率将远超个性化产品。而EVM14凭借差异化优势,在激烈的行业竞争中实现了临床开发进程的领跑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10